Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Launches New Immunoassay Kits

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Ready-to-use kits are fully qualified for reliable use in clinical research.

Merck Millipore has announced the release of five new immunoassay kits designed specifically for use on the Gyrolab™ workstation.

The new, fully qualified GyroMark™ HT kits from Merck Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, approximately 500 samples can be analyzed within four hours.

"Our collaboration with Gyros will fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform," says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at Merck Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. Merck Millipore plans to release additional kits this year, and is offering custom kits for companies with specific needs or unique or novel antibodies.

Because the Gyrolab™ platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings.

GyroMark™ HT assays provide accuracy over a four-log dynamic range (compared to two logs for ELISAs), elimination of cross-talk and plate position artifacts, and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Gyros' Global Marketing Director Maria Hjortsmark commented: "The Gyrolab™ platform revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that Merck Millipore has chosen to work with us to develop off-the-shelf kits, to further reduce time to results that will free up analyst time, and offering an easier route to robust, reproducible data."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Announces New Genomic Biomarker Services
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.
Wednesday, December 05, 2012
Scientific News
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos